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responsibility of XAbstract A simple, precise and accurate method was developed and validated for the determina-
tion of allicin release from alliin/alliinase double-layer tablets. According to Appendix XC II of
Chinese Pharmacopoeia 2010 edition Volume II, a small glass-method was adopted at the
rotational speed of 100 r/min using 100 mL phosphate buffer (pH 6.8) as release medium. The
release amount was determined by HPLC with a C18 column (250 mm 4.6 mm, 5 mm) using the
mobile phase consisting of methanol 0.4% carboxylic acid (65:35) at a ﬂow rate of 1 mL/min and
UV detection at 242 nm. The current method demonstrates good linearity over the range 4.052–
405.2 mg/mL (r2¼0.9999) with an average recovery of 105.5%(RSD¼1.25%). The accumulative
release of alliin/alliinase double-layer tablets had good homogeneity for within- and between-
batches. The method established is simple, accurate and repeatable for the determination of allicin
release from alliin/alliinase double-layer tablets.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Garlic (Allium sativum) has been advocated as a therapeutic
material for the treatment and prevention of a number ofersity. Production and hosting by E
.001
986791; fax:þ86 02885502305.
.com (L.-M. Ye)
i’an Jiaotong University.diseases [1]. Nowadays, it presents a growing interest in the
nutraceutical industry due to its capacity to form allicin, a
powerful antioxidant. Since its discovery by Cavalitto and
Bailey [2], allicin has been the best characterized biologically
active compound of garlic and shown to possess a variety of
biological effects, including antimicrobial [3,4], anti-tumor
[5–7], antifungal [8], antigenotoxic [9], and inhibitory immu-
nomodulatory [10]. Allicin is produced by an enzymatic
reaction when raw garlic is crushed or chopped. However,
the preservation of allicin is complicated by its unstable and
reactive nature; once it is generated, it readily changes into
other compounds such as allysulﬁdes, vinyldithins, andlsevier B.V. All rights reserved.
Y. Liang et al.188ajoenes [11]. Thus, stabilizing and concentrating allicin need to
be considered in depth for further commercialization of garlic
products.
In Japan and western countries, garlic products have been
popular and marketed in recent years as healthy foods with
physiologically beneﬁcial effects on humans. Consequently,
the majority of the garlic supplements sold today are garlic
powder tablets that are standardized on allicin [12]. However,
the quality of garlic products is questionable. Many garlic
products appear to undergo harsh processing [13]. In the garlic
powders, the conversion of alliin into allicin starts when the
powder meets water [14]. Allinase has been demonstrated to be
completely inactive at the acidic pH level found in the stomach
[15].
According to the disadvantages mentioned above, we
proposed that enteric coated double-layer tablet of alliin/
alliinase which was made by extracting stable chemical
property of alliin and allinase from fresh garlic and then
scientiﬁcally screening prescription to overcome unstable
property, released active ingredient of allicin in vivo to exert
full therapeutic effects. It is critical that allicin release
(actually, formation and release) from alliin/alliinase double-
layer tablets can be measured under simulated gastrointestinal
conditions. This paper focuses on developing and validating
an HPLC assay for quantitative determination of allicin
release from double-layer tablet of alliin/alliinase.2. Experimental
2.1. Apparatus and conditions
HPLC analysis was performed on an Agilent 1100 system
consisting of G1311A pump, Diamonsal C18 (250 mm 4.6
mm, 5 mm) column, G1315A UV detector and Chem-Stations
software (Agilent USA). Dissolution Apparatus (ZRS-12G,
Tianda Tianfa Technology Co., Ltd., Tianjing, China) was
used for release test. Mobile phase consisted of methanol-
water (65:35 v/v) containing formic acid (0.04%, v/v). The
injection volume was 10 mL with a ﬂow rate of 1 mL/min and
the detector wavelength was 242 nm. Ethylparaben was used
as substitute reference standard for allicin release test.2.2. Chemicals and reagents
Three batches of alliin/alliinase double-layer tablets were
provided by pharmaceutics laboratory (West China School
of Pharmacy, Sichuan University). Ethylparaben (99.9%) was
purchased from Kelun Regents Co., Ltd. (Chengdu, China).
Methanol and other solvents were of HPLC grade.2.3. Standard solutions
Standard solution was prepared by accurately weighting
20.46 mg of ethylparaben, transferring to a 50 mLvolumetric
ﬂask and dissolving in 50 mL of mobile phase. The solution
was further diluted with mobile phase to get working standard
solution with the ﬁnal concentration of 4.052, 8.104, 20.26,
32.42, 81.04, 162.1 and 405.2 mg/mL, which was used for
calibration purposes.2.4. Preparation of sample solution
Twenty alliin/alliinase tablets were ﬁnely powdered and
weighed about 10 mg for 9 samples into 25 mL volumetric
ﬂask, a quantity of ethylparaben standard was added for three
levels (0.09, 0.30, 1.50 mg). The solutions were sonicated for
1 min and volumes were made up with the mobile phase.
These solutions were used for accuracy and intermediate
precision purpose.2.5. Substitute reference standard for allicin
There is no reference standard of allicin available because it
cannot be preserved for a long time due to its extremely unstable
property and easy decomposition. By referring to the European
Pharmacopoeia 7.0 ‘‘garlic powder’’, butyl hydroxybenzoate, was
chosen as an internal standard to determine allicin content of
garlic powder. We also studied allicin and butyl hydroxybenzoate
under established chromatographic conditions. There is a large
difference in retention time between allicin and butyl hydro-
xybenzoate. That retention time can be shortened by changing
organic phase of mobile phase, but retention time of allicin can
be shortened largely, which can affect the separation of allicin
from adjacent impurities. Furthermore, Yao et al. [16] studied
chromatographic retention and separation condition of diallyl
ammonia, methylparaben, propyl hydroxybenzoate, and ethyl-
paraben with allicin. It was found that the diallyl ammonia peak
was severely deformed, that methylparaben could not be
separated from allicin, and that large differences in retention
time existed between butyl hydroxybenzoate and allicin. There-
fore, this research selected ethylparaben as a reference standard
to determine the amount of allicin release from formulations
using external standard method because of its good separation
from allicin as well as adjacent impurities.2.6. Detection of wavelength
The European Pharmacopoeia 7.0 ‘‘garlic powder’’ states that
1 mg butyl hydroxybenzoate equals to 8.65 mg allicin. Ethyl-
paraben is equal to propyl hydroxybenzoate in response
factor, but a big difference exists between allicin and ethylpar-
aben in response factor. Therefore, Yao selected the second
largest absorption wavelength of 242 nm as the detection
wavelength, where the absorption was lower than that of
254 nm, which could reduce the adjusting factor of allicin
against ethylparaben and diluting steps during determination
in order to improve the accuracy of measurement.2.7. Optimization for release test
2.7.1. Selection of release test method
Complying with Appendix XD of Chinese Pharmacopoeia
2010 edition Volume II, the rotating basket method and the
paddle method (small-glass method) were investigated respec-
tively under the conditions of 100 mL phosphate buffer
(pH¼6.8) as release medium at the rotational speed of
100 r/min.
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release test
Small glass-method was used to investigate the rotational
speed of 75 r/min and 100 r/min respectively under the condi-
tions of 100 mL phosphate buffer (pH¼6.8) as release
medium.2.7.3. Selection of release medium volume
Small glass apparatus with 100 mL release medium was used,
referring to the ﬁrst method of the release test method 2 in
Appendix XD, Chinese Pharmacopoeia 2010 edition.Fig. 1 Release curve of the rotating basket and the paddle
method.2.8. Method validation
The developed method was validated as per the International
Conference on Harmonization (ICH) [17] guidelines with
respect to linearity and range, speciﬁcity, precision, accuracy.Fig. 2 Release curves of release speed at 100 r/min and 75 r/min.3. Results and discussion
3.1. Optimization for release test
The release of the drug substance from the drug product, the
dissolution of the drug under physiological conditions and the
permeability across the gastrointestinal tract are rate-
determining steps that affect the drug absorption from a solid
dosage form after oral administration. In vitro dissolution test
can be used to predict the release and the dissolution of the
drug, hence, predict the in vivo performance of the drug. The
release test is, now, routinely employed for lot-to-lot quality
control of pharmaceuticals in solid dosage forms. We devel-
oped the release testing condition for alliin/alliinase double-
layer tablet which is not ofﬁcially available in pharmacopoeia.3.1.1. Selection of release test method
Complying with Appendix XD of Chinese Pharmacopoeia
2010 edition Volume II, the rotating basket method and the
paddle method (small-glass method) were investigated respec-
tively under the conditions of 100 mL phosphate buffer
(pH¼6.8) as release medium at the rotational speed of
100 r/min. The release curve suggested that the paddle method
was better than the rotating basket method in release extent
and rate (Fig. 1).3.1.2. Selection of rotational speed and sampling time for
release test
The rotational speeds of 75 r/min and 100 r/min were inves-
tigated respectively under the conditions of 100 mL phosphate
buffer (pH¼6.8) as release medium, applying the small glass-
method. The rotational speed at 50 r/min was not taken into
account because alliinase is a macromolecule with the mole-
cular weight ranging from 80 kDa to 100 kDa, whose dissolu-
tion in buffer solution can be increased by high rotational
speed. As shown in release curve, the result suggested that
allicin release extent and rate from each tablet with the
rotational speed of 100 r/min were higher than that at 75 r/
min (Fig. 2). Therefore, selection of the rotational speed of
100 r/min was more reasonable.3.1.3. Selection of release medium volume
Referring to the ﬁrst method of the release test method 2 in
Appendix XD, Chinese Pharmacopoeia 2010 edition, small
glass apparatus with 100 mL release medium was used. The
reasons for selection of 100 mL release medium are as follows.
At 37 1C, 1 g raw material of alliin can be fully dissolved in
2 mL deionized water whereas 0.1 g raw material of alliin
contained in each alliin/alliinase double-layer tablet can also
be fully dissolved in 100 mL release medium, and concentra-
tion is far below its saturation concentration. Therefore,
100 mL release medium always meets sink condition of
release test.3.2. Developed release test method after optimization
3.2.1. Calculation for allicin release amount
By referring to European Pharmacopoeia 7.0 ‘‘garlic powder’’
stated and Yao et al. study [16], we used ethylparabe as
substituted reference standard for allicin and the external
standard method to calculate the release of allicin. The
theoretical amount of allicin is 22.89 mg (i.e. labeled amount
of allicin) which is calculated based on that the alliinase
catalyzes two molecules allin to produce one molecular allicin
and the amount of allin contained in the alliin/alliinase
double-layer tablet. And also the peak areas of allicin and
ethylparabe were measured under the established chromato-
graphic conditions. According to relationship that 1 mg
Y. Liang et al.190ethylparabe is equivalent to 4.71 mg allicin, the amount of
allicin release was to be calculated as Eqs. (1) and (2).
The concentration of allicin release
Cx ¼
Cs  Ax  4:71
As
ð1Þ
Accumulative release of allicin (%):
Cx  V þ Cx1  V1 þ Cx2  V1 þ Cx3  V1 þ    þ Cxn  V1
22:89
 100
ð2Þ
where Cx is the concentration of allicin; Ax is the peak area of
allicin, As is the peak area of ethylparabe, V is 100 mL of
release medium volume, Cs is the concentration of ethylpar-
abe, V1 is 1 mL of sample volume for release allicin, Cx1yCxn
are the concentration of allicin at different time and 22.89 is
the theoretical release amount of allicin, namely, labeled
amount of allicin in the double-layer tablet.
The theoretical value of 22.89 mg is the total amount of
allicin which is produced from alliin by the catalysis of
alliinase under ideal conditions. But the actual allicin release
value is different from the theoretical allicin release value. The
reasons are as follows: (1) The alliin/alliinase double-layer
tablet contains 50% alliin raw material; therefore, the alliin
reacts not only with alliinase but also with other 50%
substance present in alliin raw material, which may lead to
release amount of less than 22.89 mg; (2) Alliinase, one type of
protein, whose activity is likely to be affected by temperature,
micro-environment of reaction, pH value, and the pressure of
tablet-press, giving rise to a decreased amount of catalyzed
alliin and allicin production accordingly; (3) Recipients and
other factors may prevent a small amount of alliin from
participating in reaction, thus leading to the decrease of allicin
amount generated.Fig. 3 Representative chromatograms of alliin/alliinase sample:
(a) allicin.3.2.2. Release test method
By complying with the requirements for release test (Appendix
XD II of Chinese Pharmacopoeia 2010 edition Volume II
Appendix XD 2), the small-glass-method stated in dissolution
test (Appendix XC of Chinese Pharmacopoeia 2010 edition
Volume II) was used. Firstly, 100 mL of 0.1 mol/L hydro-
chloric acid was added in each of 6 vessels as release medium,
adjusting the rotational speed to 100 r/min. This process must
ensure that each specimen does not have crevasse or disin-
tegration. The acidic medium was chosen in order to simulate
the physiological condition of the stomach. After 2 h, the acid
was drained from each of the 6 vessels and then 100 mL of
preheated phosphate buffer (pH 6.8) was added to each of the
6 vessels as release medium, and the rotational speed was not
changed. One milliliter of the solution was sampled at exactly
0, 15, 30, 40, 45, 50, 60, 75 and 90 min, respectively, ﬁltered
and the successive ﬁltrate was used as test solution.
One milliliter of fresh medium was added into each glass
immediately after the sampling. Ten milligrams of ethylpar-
aben was accurately weighed into a 25 mL volumetric ﬂask,
diluted with the mobile phase to volume and mixed well as
standard solution. The release amount of allicin from each
tablet was measured in the same manner and calculated
according to Eqs. (1) and (2).3.3. Method validation
3.3.1. Speciﬁcity
The selectivity was studied by determination of the separation
between allicin and other components in alliin/alliinase tablets.
For the analysis of tablet excipients, the data indicated that
these ingredients did not interfere in the analysis. Fig. 3 shows
a representative chromatogram of allicin, and other compo-
nents of alliin/alliinase double-layer tablet, which showed no
peaks, interfered with allicin. These results proved a good
selectivity of the proposed method.
3.3.2. Linearity
The linearity was demonstrated for ethylparaben by preparing
a seven-point calibration curve at different concentrations of
4.052, 8.104, 20.26, 32.42, 81.04, 162.1 and 405.2 mg/mL, and
each concentration was measured by three replicate injections.
The relation between the amount of ethylparaben and its peak
area was linear over the concentration range of 4.052–
405.2 mg/mL. The linear equation was: y¼0.068 103xþ
41.336 with a correlation coefﬁcient of 0.9999.
3.3.3. Precision
3.3.3.1. Repeatability. The repeatability of the method was
determined by calculating the RSD of the peak areas of six
replicate injections for the standard solution of ethylparaben,
which was found to be 0.62%, suggesting a good repeatability
for the analytical method.
3.3.3.2. Intermediate precision. Intermediate precision of the
method was also evaluated by analyzing six samples by two
analysts in the same laboratory using different HPLC systems.
The results showed that the RSD of the percentage of
ethylparaben added in the alliin/alliinase tablets for the 12
samples (6 samples from each analyst) was 1.1%, indicating a
good intermediate precision of the method.
3.3.4. Stability
The standard solution was analyzed after being exposed at the
room temperature for 0, 2, 4, 6 and 8 h and the release
solution was analyzed at 0, 1, 2, 3 and 5 h at the room
temperature. The results are shown in terms of RSD. The
RSD of standard solution and release solution was 1.6% and
2.7%, respectively, which indicated that ethylparaben
Fig. 4 Release homogeneity curve of the same batch.
Fig. 5 Release homogeneity curve for three batches.
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release solution was supposed to ﬁnish determination within
5 h.
3.3.5. Accuracy
The accuracy was tested as recovery and was determined by
spiking the accurate amount of three known levels (0.09, 0.30
and 1.50 mg) of standard to approximate 10 mg powder of
alliin/alliinase tablets. The recovery for three levels was
106.3%, 108.3% and 102%, and RSD was 1.3%, 2.3% and
0.16%, respectively. These results indicated a good accuracy
for this method.
3.4. Release homogeneity test
Complying with the release test method described in Section
3.2.2, three batches were tested for investigating the homo-
geneity of allicin release within- and between-batches. The
results shown in Fig. 4 were the results of allicin release from
the same batch and those in Fig. 5 were from the three
batches.
There was a signiﬁcant difference between each tablet in
allicin release rate and release extent, for preparation process
of these tablets was manual, such as tablet pressing and tablet
coating. In addition, to prevent stomach acid from inhibiting
alliinase, coating thickness of tablet was highly required,
which led to a lag-behind release time and a ﬁrst turning
point of allicin release of 35 min when allicin really began torelease. Therefore, this study suggested that allicin began to
release between 30 and 40 min and the release amount reached
more than 75% at exactly 60 min. Sample time of the release
test was set at exactly 35 and 60 min.4. Conclusion
In summary, double-layer tablet of alliin/alliinase, which was
not commercially available for garlic standardized on the
active compound of allicin, was a new formulation releasing
allicin by the reaction of alliin and alliinase in vivo. Therefore,
release test in vitro was optimized using the small-glass method
with 100 mL release medium and the rotational speed of 100 r/
min to rapidly test allicin. And a simple HPLC method for the
determination of allicin release amount from alliin/alliinase
double-layer tablets was developed and validated. The method
shows required linearity, precision, accuracy and selectivity for
the quantitative determination of allicin release from alliin/
alliinase double-layer tablets. Thus, the developed method can
be used for routine analysis for the quality control of allicin.
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